

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number
WO 03/106479 A2

(51) International Patent Classification⁷: C07K

(21) International Application Number: PCT/US03/19141

(22) International Filing Date: 17 June 2003 (17.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/389,649 17 June 2002 (17.06.2002) US

(71) Applicant (for all designated States except US): PARKER
HUGHES INSTITUTE [US/US]; 2699 Patton Road, Roseville, MN 55113 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventor; and

(75) Inventor/Applicant (for US only): UCKUN, Faith, M. [US/US]; 12590 Ethan Avenue North, White Bear Lake, MN 55110 (US).

(74) Agent: DAIGNAULT, Ronald, A.; Merchant & Gould P.C., P.O. Box 2903, Minneapolis, MN 55402-0903 (US).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POKEWEED ANTIVIRAL PROTEIN POLYPEPTIDES WITH ANTIVIRAL ACTIVITY

(57) **Abstract:** A molecular model of pokeweed antiviral protein (PAP)-RNA interactions was used to rationally engineer FLP-102 (¹⁵¹AA¹⁵²) and FLP-105 (¹⁹¹AG¹⁹²) as nontoxic PAP proteins with potent anti-HIV activity. FLP-102 and FLP-105 have been produced in *E. coli* and tested both *in vitro* as well as *in vivo*. These proteins depurinate HIV-1 RNA much better than ribosomal RNA and are more potent anti-HIV agents than native PAP or recombinant wild-type PAP. They are substantially less toxic than native PAP in BALB/c mice and exhibit potent *in vivo* activity against genotypically and phenotypically NRTI-resistant HIV-1 in a surrogate Hu-PBL-SLID mouse model of human AIDS. Rationally engineered nontoxic recombinant PAP proteins such as FLP-102 and FLP-105 may provide the basis for effective salvage therapies for patients harboring highly drug resistant strains of HIV-1. The documented *in vitro* potency of FLP-102 and FLP-105, their *in vivo* antiretroviral activity in HIV-infected Hu-PBL SCID mice, and their favorable toxicity profile in BALB/c mice warrant the further development of these promising new biotherapeutic agents.

WO 03/106479 A2